



Peter J. Gillies, PhD, FAHA
Professor & Founding Director

Executive Summary

Peter earned a B.Sc. in biochemistry and a Ph.D. in medical sciences from McMaster University in Canada. After postdoctoral studies in biochemical toxicology at the Chemical Industry Institute of Toxicology in Research Triangle Park, NC he joined E.I. DuPont in Wilmington, DE where he held a succession of leadership positions including Director of Cardiovascular Disease Research for DuPont Pharmaceuticals, Science Officer for DuPont Consumer Health, and Global Research Manager of Human Health Sciences for Nutrition & Health. In 2008 he was named a DuPont Fellow, the company's highest scientific rank. In 2010, Peter joined the senior leadership team at Rutgers, The State University of New Jersey, as a Professor in the Department of Nutritional Sciences and Founding Director of the New Jersey Institute for Food, Nutrition and Health. His research interests include lipid and lipoprotein metabolism, atherosclerosis, molecular nutrition of omega-3 fatty acids, and nutritional genomics. Peter is an elected fellow of the American Heart Association and the Society of Toxicology; he is also a member of several professional organizations including the American Society of Nutrition and the National Lipid Association.

Contact Information

New Jersey Institute for Food, Nutrition and Health
Rutgers, The State University of New Jersey
63 Dudley Road, Suite 122
New Brunswick, NJ 08901
Phone: 848-932-3500
Email: director@ifnh.rutgers.edu

PROFESSIONAL EXPERIENCE

2010 – present	Professor, Department of Nutritional Sciences Rutgers, The State University of New Jersey
2010 – present	Founding Director, New Jersey Institute for Food, Nutrition And Health at Rutgers
2008 – 2010	DuPont Fellow for Nutrition & Health DuPont Applied BioSciences
2006 – 2007	Senior Research Fellow Central Research & Development
2001 – 2005	Global Research Manager for Human Health Sciences DuPont Nutrition & Health
1998 - 2000	Science Officer DuPont Consumer Health
1997 - 1998	Director, General Pharmacology/Obesity DuPont Pharmaceuticals Company
1994 - 1997	Director, Cardiovascular Diseases Research The DuPont Merck Pharmaceutical Company
1991 – 1994	Associate Director, Cardiovascular Diseases Research The DuPont Merck Pharmaceutical Company
1989 - 1991	Senior Group Leader, Cardiovascular and Central Nervous System Diseases Group, DuPont Medical Products
1986 – 1989	Group Leader, Cardiovascular Science DuPont Medical Products
1983 - 1985	Principal Investigator, Cardiovascular Science Central Research and Development
1980 - 1983	Research Biochemist Haskell Laboratory for Toxicology and Industrial Medicine

EDUCATIONAL TRAINING

- 1978 – 1980 Postdoctoral Fellow, Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina, U.S.A.
- 1973 – 1978 Ph.D. (Medical Science)
McMaster University
Hamilton, Ontario, Canada.
- 1969 - 1973 B.Sc. (Biochemistry, *Summa Cum Laude*),
McMaster University
Hamilton, Ontario, Canada.

PROFESSIONAL AFFILIATIONS

- 2007- Present American Society of Nutrition
- 2007- Present National Lipid Association
- 2005 – 2007 Scientific Advisory Board; Editor of Conference Proceedings ILSI South East Asia Nutrigenomics Conference ILSI, Singapore
- 2003-2005 Technical Advisor (Genome Canada Grant)
Ethics Guidelines for Nutrigenomics
Joint Center for Bioethics
University of Toronto
- 2002–2005 Editorial Board, Journal of Nutraceuticals, Functional & Medical Foods
- 2001–2003 Scientific Advisory Board
International Conferences on Nutrigenomics
TNO, The Netherlands
- 2001-2004 Affiliate of the Institute for the Future
New Consumer: New Genetics Program
- 2001-2005 International Life Science Institute, North America
- 1998-2008 Member of the North American Association for the Study of Obesity

- | | |
|----------------|---|
| 1985 - Present | Elected Fellow of the American Heart Association
(F.A.H.A.)
Council on Arteriosclerosis |
| 1995-1998 | Editorial Board
Current Research in Cardiovascular Disease |
| 2005-Present | Elected Fellow of the Society of Toxicology
Previously a member from 1980-1987 |

ACADEMIC AFFILIATIONS

- | | |
|-----------|--|
| 2004-2010 | Adjunct Professor, Department of Nutrition Science
College of Human Development
The Pennsylvania State University
University Park, PA |
| 2003-2010 | Adjunct Professor, Department of Nutrition Science
Faculty of Medicine, University of Toronto,
Toronto, Ontario, Canada |
| 1997-2000 | Adjunct Professor, Department of Biochemistry
MCP Hahnemann University
Philadelphia, Pennsylvania, U.S.A. |
| 1980-2005 | Adjunct Professor, School of Life and Health
Sciences, University of Delaware,
Newark, Delaware, U.S.A. |

Ph.D. STUDENTS & RESEARCH FELLOWS

Hongxing Wang, MD, (1993-1996) Biochemical and molecular regulation of ACAT in human monocyte/macrophages

Aimee Christian (1998): "The use of cyclodextrins for the study of intracellular cholesterol transport and metabolism" from The Medical College of Philadelphia

Li Song (1998): "Evolution of lipid transport proteins: Analysis and characterization of two apolipoproteins from turtle, *P. Scripta*" from the University of Delaware

P. J. Gillies, Ph.D.

Page 5

Guixian Zhao (2002): "Polyunsaturated fatty acids and cardiovascular risk factors: Their effects in humans and THP-1 cells" from The Pennsylvania State University

Rodney Velliquette, Ph.D. (2005-2007) Nutritional regulation of stearoyl CoA desaturase in man.

Heather Katcher (2007): "The metabolic and reproductive effects of whole grains and high fiber foods in metabolic syndrome and polycystic ovary syndrome" from The Pennsylvania State University

Benedicte Fontain-Bisson (2008): "Nutrigenomics, inflammation and biomarkers of cardiovascular disease" from the University of Toronto

Yunkyoung Lee (2008): "Anti-inflammatory and anti-atherogenic effects of 9E,11E-conjugated linoleic acid" from The Pennsylvania State University

Jun Zhang (2009): "Identification of anti-atherogenic and anti-inflammatory effects of walnuts and pistachios" from The Pennsylvania State University.

Deepika Bangia (2014): "The impact of grocery store podcasts in the delivery of nutrition education to improve shopping behaviors, particularly the purchase of omega-3 rich foods." from Rutgers, The State University of New Jersey.

RESEARCH INTERESTS & EXPERTISE

1. Molecular nutrition (pharmacology & nutritional genomics)
2. Cardio-inflammatory disease (metabolic syndrome)
3. Lipid and lipoprotein metabolism (focus on omega-3 fatty acids)
4. Toxicology (biochemical)

SCHOLARSHIP

Ph.D. Dissertation

Gillies, P.J., Studies of carnitine metabolism in rabbit arterial tissue and plasma: Influence of dietary cholesterol, 1978. Directed by Dr. Frank P. Bell

Edited Books

1. Nutrigenomics-Opportunities in Asia. (2007) Karger Press, E.S. Tai and **P.J. Gillies**
2. Science, Society, and the Supermarket. The Opportunities and Challenges of Nutrigenomics. (2007) Wiley Press, D.C. Castle, C. Cline, A.S. Daar, C. Tsamis, P.A. Singer (member of technical expert panel)

Book Chapters

1. **Gillies, P.J.** and Vanden Heuvel, J.P. (2013) Nutrigenomic Approaches to Unraveling the Physiological Effects of Complex Foods, Chapter 4. In "Nutrigenetics and Nutrigenomics in Functional Foods and Personalized Nutrition", Taylor and Francis, Lynne Ferguson (Editor)
2. Krul, E.S. and **Gillies, P.J.** (2009) Translating Nutrigenomic Research into Practice: Soy protein as a Case Study. In "Nutrition and Genomics: Issues of Ethics, Law, Regulation and Communication", Chapter 2, pages 25-44. Academic Press, D. Castle and N. M. Ries (Editors)
3. Katcher, H.I., **Gillies, P.J.**, and Kris-Etherton, P.M. (2006) Atherosclerotic Cardiovascular Disease. In "Present Knowledge in Nutrition" Chapter 49, pages 649-668. ILSI Press, B.A. Bowman & R.M Russell (Editors)
4. Billheimer, J.T. and **Gillies, P.J.** (1990) Intracellular Cholesterol Esterification in "Advances in Cholesterol Research" Chapter 1, pages 7-45. Telford Press, M.Esfahani and J. Swaney (Editors)

Publications

Peer-Reviewed

1. Roussell, M.A., Hill, A.M., Gaugler, T.L., West, S.G., Ulbrecht, J.A., Vanden Heuvel, J.P., **Gillies, P.J.**, and Kris-Etherton, P.M. (2014). Effects of a DASH-like diet containing lean beef on vascular health. Journal of Human Hypertension. 1-6. Doi:10.1038/jhh.2014.34 (June 19, 2014)
2. **Gillies, P.J.**, Bhatia, S.K., Belcher, L.A., Hannon, D.B., Thompson, J.T., and Vanden Heuvel, P.P. (2012). Regulation of inflammatory and lipid

- metabolism genes by eicosapentaenoic acid-rich oil. *Journal of Lipid Research* 53:1679-1689.
3. Asztalos I.B., Sever, S., Gedik R., Horan M.S., Gleason, J.A., Asztalos, B.F., Horvath, K.V., Dansinger M.L., Lamon-Fava S., Laidlaw M., Holub, B., **Gillies, P.J.**, and Schaefer, E.J. (2014) Effects of eicosapentaenoic acid on serum fatty acids and inflammatory biomarkers in humans. (*Metabolism: in review*)
 4. Roussel M.A., Hill A.M., Gaugler T.L., West, S.G., Vanden Heuvel , J.P., Alaupovic, P., **Gillies, P.J.**, and Kris-Etherton, P.M. (2012). Beef in an optimal lean diet study: effects on lipids, lipoproteins, and apolipoproteins. *American Journal of Clinical Nutrition* 95:9-16.
 5. Zhang, J., Kris-Etherton, P.M., Thompson, J.T., Hannon, D.B., **Gillies, P.J.**, and Vanden Heuvel, J.P. (2012). Alpha-linolenic acid increases cholesterol efflux in macrophage-derived foam cells by decreasing stearoyl CoA desaturase 1 expression: evidence for a farnesoid-X-receptor mechanism of action. *Journal of Nutritional Biochemistry* 23:400-409.
 6. **Gillies, P.J.**, Harris, W.S., and Kris-Etherton, P.M. (2011). Omega-3 fatty acids in food and pharma: The enabling role of biotechnology. *Current Atherosclerosis Reports* 6:467-473.
 7. Zhang, J., Grieger, J.A., Kris-Etherton, P.M., Thompson, J.T., **Gillies, P.J.**, Fleming, J.A. and Vanden Heuvel, J.P. (2011).Walnut oil increases cholesterol efflux through inhibition of stearoyl CoA desaturase 1 in THP-1 macrophage-derived foam cells. *Nutrition & Metabolism* 8:61-74.
 8. Belcher, L., MacKenzie, S., Donner, M., Sykes, G., Frame, R.R., and **Gillies, P.J.** (2011) Safety assessment of EPA-rich oil produced from yeast: genotoxicity and 28-day oral toxicity in rats. *Regulatory Toxicology and Pharmacology* 59:53-63.
 9. MacKenzie, S., Belcher, L., Sykes, G., Frame, R.S., Mukerj, P., and **Gillies, P.J.** (2010) Safety assessment of EPA-rich oil produced from yeast: results of a 90-day subchronic toxicity study. *Regulatory Toxicology and Pharmacology* 58:490-500.
 10. Velliquette, R., **Gillies, P.J.**, Kris-Etherton, P.M., Green, J., Zhao, G., and Vanden Heuvel, J.P. (2009) Regulation of human stearoyl-CoA desaturase by omega-3 and omega-6 fatty acids: Implications for the dietary management of elevated serum triglycerides. *Journal of Clinical Lipidology* 3:281-288.
 11. Katcher, H.I., Legro, R.S., Kunselman A.R., **Gillies, P.J.**, Demers, L.M., Bagshaw, D.M., and Kris-Etherton, P.M. (2008). The effects of a whole grain enriched hypocaloric diet on cardiovascular disease risk factors in

- men and women with metabolic syndrome. *American Journal of Clinical Nutrition* 87:79-90.
12. Zhao, G., Etherton T.D., Martin, K.R., **Gillies, P.J.**, West, S.G., and Kris-Etherton, P.M. (2007) Dietary α -linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. *American Journal of Clinical Nutrition* 85: 385-391.
 13. **Gillies, P.J.** and Krul, E.S., (2007) Using genetic variation to optimize nutritional preemption. *Journal of Nutrition* 137:270S-274S.
 14. GeBauer, S., **Gillies, P.**, Vanden Heuvel, J., and Kris-Etherton, P. Integration of Molecular Biology and Nutrition: The Role of nutrigenomics in optimizing guidance for dietary fatty acids. (2007). *Future Lipidology* 2:165-171.
 15. Vanden Heuvel, J.P., Thompson, J.T., Frame, S.R., and **Gillies, P.J.** (2006) Differential activation of nuclear receptors by normal and perfluorinated fatty acids: A comparison of human, mouse and rat PPAR α β γ , LXR β and RXR α . *Toxicological Sciences* 92:476-489.
 16. Kaput, J., Ordovas, J.M., Ferguson, L...**Gillies, P.J.** ...etal (2005) The case for strategic international alliances to harness nutritional genomics for public and personal health. *British Journal of Nutrition* 94:623-632.
 17. Loveless, S.E., Finlay, C, Everds, N.E., Frame, S.R., **Gillies, P.J.**, O'Connor, J.C., and Kennedy, G.L. (2005). Comparative responses of rats and mice exposed to linear/branched, linear or branched ammonium perfluorooctanoate (APFO) toxicology. 220:203-217.
 18. Zhao, G., Etherton, T.D., Martin, K.R., Vanden Heuvel, J.P., **Gillies, P.J.**, and Kris-Etherton, P.M. (2005). Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 Cells. *Biochem. Biophys Res Comm.* 336: 909-917.
 19. Zhao, G., Etherton, T.D., Martin, K.R., West, S.G., **Gillies, P.J.**, and Kris-Etherton, P.M. (2004) Dietary Alpha-Linolenic acid reduces inflammatory and cardiovascular risk factors. *J. Nutrition* 134: 2991-2997.
 20. **Gillies, P.J.** (2003) Nutrigenomics: The Rubicon of molecular nutrition. *Journal of the American Dietetic Association* 103(12): Supplement 2, 50-55.
 21. Snyder, R.D. and **P.J. Gillies** (2003) Reduction of genistein clastogenicity in Chinese Hamster V79 cells by daidzein and other flavonoids. *Food and Chemical Toxicology* 41: 1291-1298.
 22. Snyder, R.D. and **P. J. Gillies** (2002) Evaluation of the clastogenic, DNA intercalative and topoisomerase-II interactive properties of bioflavonoids

- in Chinese hamster V79 cells. *Environmental and Molecular Mutagenesis* 40:266-276.
23. **Gillies, P.J.** (1998) Drug Evaluation: DMP 504. *Current Research in Vascular Diseases* 3:8-10.
 24. Shimshick, E.J., Figuly, G.D., Grimminger, L.C., Hainer, J.W., Jensen, J.H., Leipold, R.J., Royce, S.D., and **Gillies, P.J.** (1997). DMP 504, a novel hydrogel bile acid sequestrant: I. Equilibrium binding properties and computer simulation of human bile flow. *Drug Development Research* 41:58-64.
 25. **Gillies, P.J.**, Billheimer, J.T., Blackston, V.A., Cromley, D.A., Figuly, G.D., Fischer, R.T., Germain, S.J., Godonis, H.E., Gorko, M.A., Grimminger, L.C., Harvey, S.J., Jensen, J.H., Kieras, C.J., Royce, S.D., Pautler, H.C., Shimshick, E.J., Stevenson, R.C., and Hainer, J.W. (1997). DMP 504, a novel hydrogel bile acid sequestrant: II. Lipid-lowering pharmacology in the hamster. *Drug Development Research* 41:65-75.
 26. Hainer, J.W., Hunninghake, D.B., Benedek, I.H., Broyles, F.E., Garner, D.M., Jenkins, R.M., McGinna, A., Pieniaszek, H.J., London, E., and **Gillies, P.J.** (1997). DMP 504, a novel hydrogel bile acid sequestrant: III. Safety, tolerability, and cholesterol-lowering in healthy hypercholesterolemic subjects. *Drug Development Research* 41:76-84.
 27. Figuly, G.D., Royce, S.D., Khasat, N.P., Schock, L.E., Wu, S.D., Davidson, R., Campbell, G.C., Keating, M.Y., **Gillies, P.J.**, Chen H.W., Shimshick, E.J., Fischer R.T., Grimminger, L.C., Thomas, B.E., and Smith, L.H. (1997). Preparation and characterization of novel polyalkylamine based hydrogels. *Macromolecules* 30:6174-6184.
 28. Wang, H., German, S.J., Benfield, P.P., and **Gillies, P. J.** (1996). Gene expression of acyl-CoA: cholesterol acyltransferase is upregulated in human monocytes during differentiation and foam cell formation. *Arteriosclerosis, Thrombosis and Vascular Biology*, 16:809-814.
 29. Boswell, G.A., Li, H.Y., Delucca, I., Billheimer, J.T., Drummond, S., **Gillies, P.J.**, and Robinson, C. (1996). Novel 4,4-bis(trifluoromethyl)imidazolines as stereospecific and orally active acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents. *Bioorganic and Medicinal Chemistry Letters*, 6:885-888.
 30. Wilde, R.G., Billheimer, J.T., Germain, S.J., Hausner, E.A., Meunier P.C., Munzer, D.A., Stoltenborg, J.K., **Gillies, P.J.**, Burcham, D.L., Huang, S.M., Klaczkiwicz, J.D., Ko, S.S., and Wexler, R.R. (1996). ACAT inhibitors derived from hetero-Diels-Alder cycloadducts of thioaldehydes. *Bioorganic and Medicinal Chemistry* 4:1493-1513.

31. Wilde, R. G., Billheimer, J. T. Germain, S. J., **Gillies, P. J.**, Higley, C.A., Kezar, H.S. III, Maduskuie, T.P., Shimshick, E. J., and Wexler, R. R. (1995). Acyl-CoA: Cholesterol acyltransferase (ACAT) inhibitors: Ureas bearing heterocyclic groups bioisosteric for an imidazole. *Biomedical Chemistry Letters*. 5: 167-172.
32. Maduskuie, T. P., Wilde R.G., Billheimer, J. T., Cromley D.A., Germain, S. J., **Gillies, P. J.**, Higley, C. A., Johnson, A. L., Pennev, P., Shimshick, E. J., and Wexler, R. R. (1995). Design, synthesis and SAR studies for a new imidazole series of J774 macrophage specific acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors. *Journal of Medicinal Chemistry*, 38: 1067-1083.
33. Wilde, R. G., Klaczkiewicz, J.D., Billheimer, J. T., Wexler, R.R., and **Gillies, P. J.** (1995). Acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors: Heterocyclic bioisosteres for the urea group in DuP 128. *Biomedical Chemistry Letters*, 5, 177-180.
34. Hausner, E.A., Schlingmann, K.L., Chen, H.W., **Gillies, P.J.**, Kieras, C.J., Ross, P.E., and VanPelt, C. (1995). Hepatic and adrenal changes in rabbits associated with the hyperlipidemia caused by a semi-synthetic diet. *Laboratory Animal Science*, 45:663-670.
35. Kinter, M., Robinson, C. S., Grimminger, L. C., **Gillies, P. J.**, Shimshick, E. J., and Ayers, C. (1994). Whole blood and plasma concentrations of 4-hydroxy-2-nonenal in Watanabe Heritable Hyperlipidemic versus New Zealand White Rabbits. *Biochemical and Biophysical Research Communications*, 199: 671-675.
36. Hainer, J. W., Terry, J. G., Connell, J. M., Zyruk, H., Jenkins, R. M., Shand, D. L., **Gillies, P. J.**, Livak, K. L., Hunt, T. L., and Crouse, J. R., (1994). Effect of the ACAT inhibitor DuP 128 on cholesterol absorption and serum cholesterol in man. *Clinical Pharmacology and Therapeutics*, 56: 65-74.
37. Huff, M. W., Telford, D. E., Barrett, P. H. R., Billheimer, J. T. Billheimer, and **Gillies, P. J.** (1994). Inhibition of hepatic ACAT decreases apolipoprotein B secretion in miniature pigs fed a cholesterol-free diet. *Arteriosclerosis and Thrombosis*, 14:1498-1508.
38. Higley, C. A., Wilde, R.G., Maduskuie, T. P., Johnson, A. L., Pennev, P., Billheimer, J.T., Robinson, C.S., **Gillies, P. J.**, and Wexler, R. R. (1994). Acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors: Synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles. *Journal of Medicinal Chemistry*, 37: 3511-3522.
39. Pease, L. J., Robinson, C.S., **Gillies, P. J.**, Bozarth, J., Reilly, T. M., and Mousa, S. A. (1993). Increased platelet GP IIb/IIIa receptor sensitivity in

- Watanabe Heritable Hypercholesterolemic rabbits. *Biochemical Archives*, 9:311-320.
40. Merickel, M. B., Beer, S., Spetz, K., Jackson, T. R., Snell, J., **Gillies, P. J.**, Shimshick, E. J., Brookeman, J. R., and Ayers, C. A. (1993). Non-invasive quantitative evaluation of atherosclerosis utilizing MRI and image analysis. *Arteriosclerosis and Thrombosis*, 13: 1180-1186.
 41. **Gillies, P. J.**, Robinson, C. S. and Rathgeb, K. A. (1990). Regulation of ACAT activity by a cholesterol substrate pool during the progression and regression phases of atherosclerosis: Implications for drug discovery. *Atherosclerosis* 83, 177-185.
 42. **Gillies, P. J.**, Robinson, C. S., Cockrell, B. Y. and Graepel, G. J. (1989). Effect of lanthanum chloride on established atherosclerosis in the cholesterol-fed rabbit: Mitral valve as a site for assessment of treatment effects. *Arteriosclerosis* 9, 253-260.
 43. **Gillies, P. J.** and Robinson, C. S. (1988). Decreased plasma membrane fluidity in the development of atherosclerosis in cholesterol-fed rabbits. *Atherosclerosis* 70, 161-164.
 44. Vincent, D. R., **Gillies, P. J.**, Lee, K. P., Wood, C. K. and Arthaud, L. E. (1988). Alterations in lipid metabolism and cellular morphology in the liver of female rats treated with Ethmozine. *Toxicology and Applied Pharmacology* 95, 456-463.
 45. **Gillies, P. J.**, Robinson, C. S., and Chapple, R. P. (1987). Differential effects of hypercholesterolemia on the membrane fluidity of intimal-medial vs medial layers of swine aorta: Implications for the development of arterial vasospasm. *Experimental and Molecular Pathology* 47, 90-97.
 46. Pastoor, T. P., Lee, K. P., Perri, M. A. and **Gillies, P. J.** (1987) Biochemical and morphological studies of ammonium perfluorooctanoate induced hepatomegaly and peroxisome proliferation. *Experimental and Molecular Pathology* 47, 98-109.
 47. Lee, K. P. and **Gillies, P. J.** (1986). Pulmonary response and intrapulmonary lipids in rats exposed to bismuth orthovanadate dust by inhalation. *Environmental Research* 40, 115-135.
 48. **Gillies, P. J.**, Rathgeb, K. A., Perri, M. A., and Robinson, C. S. (1986). Regulation of acyl-CoA: cholesterol acyltransferase activity in normal and atherosclerotic rabbit aortas: Role of a cholesterol substrate pool. *Experimental and Molecular Pathology* 44, 329-339.
 49. Robinson, C. S. and **Gillies, P. J.** (1986). Decreased microsomal membrane fluidity in the development of cholesterol-induced atherosclerosis in the rabbit. *Experimental and Molecular Pathology* 45, 294-302.

50. **Gillies, P. J.** and Lee, K. P. (1985). Effects of hexafluoroacetone on Leydig cell steroidogenesis and spermatogenesis in the rat. *Experimental and Molecular Pathology* 42, 353-365.
51. **Gillies, P. J.** and Rickard, R. W. (1984). Toxicokinetics of [14C] hexafluoroacetone in the rat. *Toxicology and Applied Pharmacology* 73, 23-29.
52. Lee, K. P. and **Gillies, P. J.** (1984). Ultrastructural alterations in hexafluoroacetone-induced testicular atrophy in the rat. *Experimental and Molecular Pathology* 40, 29-37.
53. **Gillies, P. J.** and Lee, K. P. (1983). Effects of hexafluoroacetone on testicular morphology and lipid metabolism in the rat. *Toxicology and Applied Pharmacology* 68, 188-197.
54. Bus, J. S., White, E. L., **Gillies, P. J.**, and Barrows, C. (1981). Tissue distribution of n-hexane, methyl n-butyl ketone and 2,5-hexanedione in rats after single and repeated inhalation exposure to n-hexane. *Drug Metabolism and Disposition* 9, 386-387.
55. **Gillies, P. J.**, Norton, R. M., and Bus, J. S. (1981). Inhibition of sterologogenesis but not glycolysis in 2,5-hexanedione-induced peripheral neuropathy. *Toxicology and Applied Pharmacology* 59, 287-292.
56. **Gillies, P. J.**, Norton, R. M., Baker, T. S., and Bus, J. S. (1981). Altered lipid metabolism in 2,5-hexanedione-induced testicular atrophy and peripheral neuropathy. *Toxicology and Applied Pharmacology* 59, 293-299.
57. **Gillies, P. J.**, Norton, R. M., and Bus, J. S. (1980). Effect of 2,5 hexanedione on lipid biosynthesis in sciatic nerve and brain of the rat. *Toxicology and Applied Pharmacology* 54, 210-216.
58. **Gillies, P. J.**, Norton, R. M., White, E. L., and Bus, J. S. (1980). Inhibition of sciatic nerve sterologogenesis in hexacarbon-induced distal axonopathy in the rat. *Toxicology and Applied Pharmacology* 54, 217-222.
59. Bell, F. P., Patt, C. S., and **Gillies, P. J.** (1979). Plasma carnitine and cholesterol levels in monkeys and pigeons: Species/breed differences and the influence of gender and diet. *Comparative Biochemistry and Physiology* 63B, 215-219.
60. **Gillies, P. J.** and Bell, F. P. (1979). Uptake and esterification of circulating carnitine by aorta and heart in rabbits, in vivo: Influence of dietary cholesterol. *Atherosclerosis* 33, 99-109.
61. **Gillies, P. J.** and Bell, F. P. (1979). Carnitine palmitoyl-transferase activity in mitochondrial fractions isolated from aortas of rabbits fed cholesterol-supplemented diets. *Atherosclerosis* 34, 25-34.

62. Bell, F. P., Patt, C. S., Brundage, B., **Gillies, P. J.**, and Phillips, W. A. (1978). Studies on lipid biosynthesis and cholesterol content of liver and serum lipoproteins in rats fed various phthalate esters. *Lipids* 13, 66-74.
63. Bell, F. P., Patt, C. S., and **Gillies, P. J.** (1978). Effect of phthalate esters on serum cholesterol and lipid biosynthesis in liver, testes, and epididymal fat in the rat and rabbit. *Lipids* 13, 673-678.
64. Bell, F. P. and **Gillies, P. J.** (1977). Effect of dietary di-2-ethyl-hexylphthalate on oxidation of ¹⁴C-palmitoyl CoA by mitochondria from mammalian heart and liver. *Lipids* 12, 581-585.
65. **Gillies, P. J.** and Bell, F. P. (1976). Arterial and plasma carnitine levels in rabbits: Influence of age and dietary cholesterol. *Experimental and Molecular Pathology* 25, 402-411.
66. Niewiarowski, S., Senyi, A. F., and **Gillies, P. J.** (1973). Plasmin-induced platelet aggregation and platelet release reaction. *Journal of Clinical Investigation* 52, 1647-1659.

Published Conference Proceedings

67. **Gillies, P.** and Kris-Etherton, P. (2010). Opportunities and challenges in nutrigenetics/nutrigenomics: Building industry-academia partnerships. *World Reviews of Nutrition and Dietetics* 101:160-168.
68. **Gillies, P.** (2007) Nutrigenomics: Industry's perspective in NAS workshop report "Nutrigenomics and Beyond: Informing the Future" The National Academies Press, Yaktine & Poole, Eds) pages 50-54.
69. **Gillies, P.** (2007) Pre-emptive nutrition of pro-inflammatory states: A nutrigenomic model. *Nutrition Reviews* 65:S217-S220.
70. **Gillies, P.J.** (2001) Nutrigenomics: A global health perspective. Proceedings of the International Congress for Global Health Equity, Paris, France.

FDA Regulatory Filings and Patents

71. Investigational New Drug Application: IND No: Project DMP 504 (1996), Hainer, J.W. and **Gillies, P.J.** A Novel Bile Acid Sequestrant for the Treatment of Hypercholesterolemia. June 25, 1996, AMANDA 1009600269, FDA
72. Investigational New Drug Application: IND No.36,018; Project DuP 128 (1993) Hainer, J.W. and **Gillies, P.J.** A Novel ACAT Inhibitor for the

Treatment of Hypercholesterolemia. April 30, 1993, AMANDA 1009301392, FDA.

73. **Gillies, P.J.** and Schaefer, E.J. (2013) Clinical benefits of eicosapentaenoic acid in humans. United States Patent Application No. CL4938-US-CNT[1] filed May 24, 2013.
74. Damude, H.G., **Gillies, P.J.**, Macool, D.J., Picataggio, S.K., Pollak, D.M.W., Raghianti, J.J., Xue, Z, Yadav, N.S., Zhang, H., and Zhu, Q.Q. High arachidonic acid producing strains of *Yarrowia Lipolytica*. United States Patent Application 20060094092 A1, May 4, 2006
75. Damude, H.G., **Gillies, P.J.**, Macool, D.J., Picataggio, S.K., Pollak, D.W., Raghianti, J.J., Xue, Z., Yadav, N.A., Zhang, H., and Zhu, Q.Q. High Eicosapentaenoic acid producing strains of *Yarrowia Lipolytica*. United States Patent No. 8,518,674 August 27, 2013
76. Damude, H.G., **Gillies, P.J.**, Macool, D.J., Picataggio, S.K., Pollak, D.W., Raghianti, J.J., Xue, Z., Yadav, N.A., Zhang, H., and Zhu, Q.Q. High Eicosapentaenoic acid producing strains of *Yarrowia Lipolytica*. United States Patent No. 8,815,566 August 26, 2014
77. Damude, H.G., **Gillies, P.J.**, Macool, D.J., Picataggio, S.K., Raghianti, J.J., Xue, Z., Yadav, N.A., Zhang, H., Zhu, Q.Q., and Seip, J.E. Docosaehaenoic acid producing strains of *Yarrowia Lipolytica*. United States Patent Application No. 8,685,682 April 1, 2014
78. Billheimer, J. T., Boswell, G. A., Deluca, I., Drummond, Jr., S., **Gillies, P. J.** and Trzaskos, J. M. (1995). Antihypercholesterolemic bis-trifluoromethyl substituted imidazolines and derivatives thereof. U.S. Patent No. 5,428,041
79. Billheimer, J. T., **Gillies, P. J.**, Higley, C. A., Maduskuie, T. P., and Wexler, R. R. (1994). Imidazoles for the treatment of atherosclerosis. U. S. Patent Number 5,318,984.
80. Billheimer, J. T., **Gillies, P. J.**, Higley, C. A., Maduskuie, T. P. and Wexler, R. R. (1992). Imidazoles for the treatment of atherosclerosis. U. S. Patent Number 5,166,214. **[78]** Billheimer, J. T., **Gillies, P. J.** and Wilkerson, W. W. (1990). Antihypercholesterolemic 4,5-diaryl-2-substituted thioimidazoles. U.S. Patent Number 4,900,744

Keynote/Plenary Addresses

1. Gillies, P.J. (2014) Health: The Rubik's Cube of Life, 2014 Healthcare Symposium: Food for Thought: Reducing Costs Through Wellness, September 23rd Princeton Chamber of Commerce, NJ

2. Gillies, P.J. (2012) Nutrition is Alive and Well at Rutgers. Annual Continuing Education Health Conference, " Changing Times, Changing Students, Changing Student Responses" January 10th Rutgers University, New Brunswick, NJ
3. Gillies, P.J. (2011) Clinical Evaluation of Eicosapentaenoic Acid: Effects on Lipoprotein Metabolism and Vascular Inflammation. March 9th, University of Medicine and Dentistry of New Jersey. Medical Grand Rounds. Robert Wood Johnson School of Medicine, New Brunswick, NJ.
4. Gillies, P.J., (2011) Eat Well Live Well, 13th Annual Conference, New Jersey Foundation for Aging
5. Gillies, P.J. (2011) Eat Well Live Well. New York and Central New Jersey Chapter of the Institute for Food Technology. February 8th, New Brunswick, NJ.
6. Gillies, P.J. (2011) Ernest Mario School of Pharmacy Commencement Address. "The Future is Yours to Invent" May 16th Rutgers University, New Brunswick, NJ
7. Gillies, P.J. (2011) Omega-3 Fatty Acids in Food and Pharma: The Enabling Role of Biotechnology. UC Davis Biotechnology Program, October 14 David, CA
8. Gillies, P.J. (2010) Eat Well, Live Well. Dinner Speaker at the 3rd Annual Pioneers in Endocrinology Conference. Rutgers University, New Brunswick, NJ.
9. Gillies, P.J. (2010) Pre-emptive nutrition in the dietary management of health: Implications for the New Jersey Institute for Food, Nutrition and Health. Dean's Distinguished Lecture Series, May, New Brunswick, NJ.
10. Gillies, P.J. (2010) The new science of omega-3 fatty acids. Plenary lecture at the 37th Annual Texas Human Nutrition Conference, February, Texas A&M University, College Station, TX
11. Gillies, P.J. (2009) Frontiers in nutrigenetics/nutrigenomics: Opportunities and challenges. Plenary lecture at the International Society of Nutrigenetics/Nutrigenetics, October, Washington DC
12. Gillies, P.J. (2007) Nutrigenomic approaches to defining the health benefits of natural Health Products. Plenary lecture at the National Health Products Research Society of Canada, May, Saskatoon, SK, Canada
13. Gillies, P.J. (2007) Long-chain omega-3 fatty acids in the dietary management of metabolic syndrome: A nutrigenomic approach. Plenary lecture at the Agricultural Biotechnology International Conference, September, Calgary, AB, Canada

14. Gillies, P.J. (2007) Omega-3 fatty acids in the dietary management of pro-inflammatory states: A nutrigenomic model. Distinguished Lecture, March, National Institutes of Health, Bethesda, MD
15. Gillies, P.J. (2006) Nutrigenomics Today, Keynote address at the Canadian Nutrigenomics Workshop, October, Montreal, QE, Canada
16. Gillies, P.J. (2006) Nutrigenomics: An industry perspective. Plenary lecture at the Canadian Nutrigenomics Workshop, October, Montreal, QE, Canada
17. Gillies, P.J. (2006) Nutrigenomic approaches to understanding the health benefits of omega-3 fatty acids. Plenary lecture at the International Conference on the Molecular Biology of the Soybean, August, Lincoln, NE
18. Gillies, P.J. and Krul, E.S. (2006) Using genetic variation to optimize nutritional preemption. Plenary lecture at the International Conference on Food, Nutrition and Cancer, July, Washington, DC
19. Gillies, P.J. (2006) The future of nutrigenomics and nutrigenetics: Industry Perspective. Plenary lecture at the Institute of Medicine: Food & Nutrition Workshop, June, Washington, DC
20. Gillies, P.J. (2005) New frontiers in the regulation of lipid metabolism: The food-pharma blur. Plenary lecture at the DACC conference on "Trafficking in lipoproteins" April, Princeton, NJ
21. Gillies, P.J. (2002) Introducing nutrigenomics: Implications for doctors, dieticians, and dietary guidelines. Plenary lecture at Annual Food Update Forum, April, Key Biscayne, FL
22. Gillies, P.J. (2002) Linking scientific research to dietary guidelines: Implication of the human genome project. Plenary lecture at the Joint ILSI-University of Toronto Conference, April, Toronto, ON, Canada
23. Gillies, P.J. (2002) Nutrigenomics: A New Frontier in Health Promotion. Plenary lecture at the First International Conference on Nutrigenomics, February, Noordwijk aan Zee, The Netherlands.
24. Gillies, P. J. (2001) Specialized uses of databases in health and disease research. Keynote address at the 25th Conference on Nutrient Databanks, FASEB symposium, Orlando, FL
25. Gillies, P.J. (2001) The future of pharmaceuticals and medicinals: Blurring the boundaries between food and drugs. Keynote address at the Institute for the Future Health Care Horizons Conference, June, Chicago, IL
26. Gillies, P.J. (2001) Nutrigenomics: A global health perspective. Plenary lecture at the 4th International Conference on Global Health Equity, UNESCO. Paris, France

27. Gillies, P.J. (2000) Molecular nutrition and nutrigenomics. Keynote address at the General Mills Technical Conference, Minneapolis, MN
28. Gillies, P.J. (2000) Implications of genomics on the management of health and disease: Blurring the boundaries between drugs and foods. Keynote address at the American Healthways Annual Physicians Meeting in Nashville, TN

Invited Lectures

1. Gillies, P.J. (2014) GBK Distinguished Lecture: Molecular Pharmacology of Eicosapentaenoic Acid, February 19th Genesis Biotechnology Group, Hamilton NJ
2. Gillies, P.J. (2011) Safety Evaluation of Eicosapentaenoic Acid. EOHSI, Rutgers University, February 3rd. Piscataway, NJ.
3. Gillies, P.J. and Stoler, F. (2011) Scientists are from MARS and Marketers are from VENUS. Professional Science Masters Program, Rutgers University, February 21. Piscataway, NJ.
4. Gillies, P.J. (2011) The Intersection of Nutritional and Medical Pharmacology, Department of Nutrition, Rutgers University, November, New Brunswick, NJ.
5. Gillies, P.J. (2011) Introduction to Global Public Health, UMDNJ School of Public Health, November. Piscataway, New Jersey
6. Gillies, P.J. (2008) Regulation of stearyl-CoA desaturase by omega-3 and omega-6 fatty acids. Invited lecture, The Pennsylvania State University, November, State College, PA
7. Gillies, P.J. (2007) Omega-3 R&D at DuPont: A look behind the oval. Invited lecture, University of Toronto, November, Toronto, ON, Canada
8. Gillies, P.J., Kris-Etherton, P.M. and Vanden Heuvel, J.P. (2007) Preemptive nutrition of pro-inflammatory states: A nutrigenomic model. Invited lecture, Rutgers University, February, New Brunswick, NJ
9. Gillies, P.J., Kris-Etherton, P.M. and Vanden Heuvel, J.P. (2007) Preemptive nutrition of pro-inflammatory states: A nutrigenomic model. Invited lecture, Tufts University Conference: Living Well to 100, November, Boston, MA

10. Gillies, P.J. (2006) Nutrigenomic approaches to understanding the nutritional pharmacology of PUFAs. Invited lecture, Cornell University, April, Ithaca, NY
11. Gillies, P.J. (2006) Nutrigenomic approaches to understanding the nutritional pharmacology of PUFAs. Invited lecture, The Pennsylvania State University, February, State College, PA
12. Gillies, P.J. (2005) The role of molecular nutrition in the development of portfolio diets to manage cardio-inflammatory disorders. Invited lecture, University of Iowa School of Public Health, April, Iowa City, IA.
13. Gillies, P.J., Kris-Etherton, P.M., and Vanden Heuvel, J.P. (2005) Impact of molecular nutrition on the safety assessment of food bioactives. Invited workshop lecture at the annual meeting of the Society of Toxicology, March, New Orleans, LA.
14. Gillies, P.J. (2004) What is your molecular age? Invited presentation at the Tufts University conference on "Living Well to 100", November, Boston, MA.
15. Gillies, P.J. (2004) The hope and hype of nutrigenomics! Invited lecture, University of Delaware, March, Newark, DE
16. Gillies, P.J. (2004) Navigating the realities of nutrigenomics. Invited lecture, University of Toronto, February, Toronto, ON. Canada
17. Gillies, P.J. (2003) Nutrigenomics. Invited lecture, University of Minnesota, December, St. Paul, MN.
18. Gillies, P.J. (2003) Nutrigenomic profiling of soy isoflavones: Implications for chemoprevention. Invited lecture, 2nd International Nutrigenomics Conference, November, Amsterdam, The Netherlands.
19. Gillies, P.J. (2003) The hope and hype of nutrigenomics. Invited lecture, The Pennsylvania State University, October, State College, PA
20. Gillies, P.J. (2003) Molecular Nutrition: Nutrigenomics to nutrigenetics. Invited lecture, University of Delaware, May, Newark, DE.
21. Gillies, P.J. (2002) Nutritional genomics: Implications of the human genome project to health and nutrition sciences. Invited lecture, University of Delaware, Newark, DE

22. Gillies, P.J. (2002) Consumer reactions at the cross roads of genomics, food and the internet. Invited lecture, University of Delaware, April, Newark, DE
23. Gillies, P.J., Germain, S.J., and Wang, H.X. (1994) Biochemical and molecular regulation of ACAT in human monocytes, macrophages and foam cells. Invited lecture, Philadelphia Lipid Club, Collegeville, PA
24. Gillies, P.J. (1993) Studies on the progression and regression of atherosclerosis. Invited lecture, Medical College of Pennsylvania, Philadelphia, PA
25. Gillies, P.J. (1988) Approaches to the study of the regression of atherosclerosis in the rabbit, Invited lecture, Smith, Kline, French Laboratories, London, England
26. Gillies, P.J. (1986) Regulation of arterial ACAT activity. Invited lecture, Philadelphia Lipid Club, Philadelphia, PA
27. Gillies, P.J. (1983) Hexafluoroacetone: studies of its mechanism of action. Invited lecture, Smith Kline Beckman Laboratories, Philadelphia, PA
28. Gillies, P.J. (1981) The biochemical lesions in 2,5-hexanedione-induced peripheral neuropathy. Invited lecture, Institute of Neurotoxicity, Albert Einstein College of Medicine, Bronx, NY
29. Gillies, P.J., Norton, R.M., and Bus, J.S. (1979) Effect of 2,5-hexanedione-induced distal axonopathy in the rat. Invited lecture, American Petroleum Institute, Washington, DC

Presentations at Scientific Conferences

1. Vanden Heuvel, J.P., Bhatia, S.K., Belcher L.A., Thompson J.T., and Gillies, P.J. (2012) Regulation of inflammatory and lipid metabolism genes by eicosapentaenoic acid-rich oil. Presented at Experimental Biology, April 23, San Diego, CA
2. Schaefer, E.J., Asztalos, I.B., Gleason, J.A., Asztalos, B.F., Horvath, K., Dansinger, M.L., and Gillies, P.J. (2010) Effects of eicosapentaenoic acid, docosahexaenoic acid, and olive oil on cardiovascular disease risk factors. Presented at the Annual Meeting of the American Heart Association, November, Chicago, IL

3. Gillies, P.J., (2010) Alternative sources of omega-3 fatty acids: The role of biotechnology. Presented at the 1st Annual Conference of the American Council for Medicinally Active Plants, Rutgers University, July, New Brunswick, NJ
4. Liang, SC, Tyreus, B., Powley, C., Gillies, P., Spahr, D., (2010) Processing EPA oil from *Yarrowia Lipolytica*: A new, sustainable source for a dietary ingredient. Presented at the 101st Annual meeting of the American Oil Chemists Society, Phoenix, AZ.
5. Munley, S.M., Donner, E.M., Belcher, L., and Gillies, P. (2010) Evaluation of the potential toxicity and genotoxicity of yeast oil containing eicosapentaenoic acid. Presented at the annual meeting of the Society of Toxicology, Salt Lake City, UT, March 2010.
6. MacKenzie, S., Belcher, L., Sykes, G., Frame, S.R., and Gillies, P (2010) Safety assessment of a 28-day repeated-dose exposure to an EPA-rich oil produced from yeast. Presented at the annual meeting of the Society of Toxicology, Salt Lake City. UT, March 2010.
7. Belcher, L., MacKenzie, S.M., Sykes, G., Frame, S.R., Mukerji, P., and Gillies, P (2010). Safety assessment of a 90-day subchronic exposure to an EPA-rich oil produced from yeast. Presented at the annual meeting of the Society of Toxicology, Salt Lake City, UT, March 2010.
8. Velliquette, R., Gillies, P.J., Kris-Etherton, P.M., Green, J., Zhao, G., and Vanden Heuvel, J.P. (2008) Regulation of stearyl-CoA desaturase by omega-3 fatty acids: Implications for the dietary management of metabolic syndrome. 7th International Symposium on Multiple risk Factors in Cardiovascular Diseases, October, 23rd Venice, Italy.
9. Gillies, P. (2005) Developing a molecular context for the biological effects of PFOA. Health Canada, September 14th Ottawa, ON, Canada
10. John P. Vanden Heuvel, J., Thompson, J., Frame, R., and Gillies, P. (2005) Differential activation of nuclear receptors by normal and perfluorinated fatty acids: A comparison of human, mouse and rat PPAR- $\alpha/\beta/\gamma$ LXR- β and RXR- α , Fluoros Symposium, August 19th Toronto, ON, Canada
11. Loveless, S, Finlay, C, Everds, N., Frame, R., Gillies, P., O'Connor, J., and Kennedy, G. (2005). Comparative responses of rats and mice exposed to linear/branched. linear or branched ammonium perfluorooctanoate (APFO). Fluoros Symposium, August 19th Toronto, ON, Canada
12. Gillies, P. (2005) Developing a molecular context for the biological effects of PFOA. FDA, June 27th Washington DC

13. Gillies, P. (2005) Developing a molecular context for the biological effects of PFOA. EPA, May 4th Washington DC.
14. Gillies, P., P.M Kris-Etherton, and John P. Vanden Heuvel (2005) Impact of Molecular Nutrition on the Safety Assessment of Food Bioactives. Annual Meeting of the Society of Toxicology Workshop on "The Role of Nutrigenomics in the Safety Assessment of Functional Foods," March 7th, New Orleans, LA
15. Gillies, P. Smith, H., van Ommen, B., and Stierum, R. (2003) Nutrigenomic Profiling of Soy Isoflavones: A Comparison of the Effects of Genistein and Daidzein on a Human Gut Epithelial Cell-line Transcriptome. 5th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, September 21-24th, Orlando, FL
16. Lawrence, K., Taylor, R., Johnson, J., Albu, J., Gillies, P. (2000) Hydroxy-steroid dehydrogenase-1 (HSD1) expression is not dysregulated in obesity. Presented at the Annual Meeting of the North American Association for the Study of Obesity
17. Mousa, S., Forsythe, M., Bozarth, J., Gillies, P. (1999) Platelet and vascular-mediated effects of soy bioactive components. Presented at the American Society of Hematology
18. Corjay, M.H., Diamond, S.M., Kearney, M.A., Hongxing, W., Gillies, P.J., and Stoltenborg, J.K. (1996). The anti-proliferative gene, BTG1, is upregulated in cultured human monocyte-derived foam cells and is highly expressed in macrophage-rich areas of advanced lesions in the WHHL rabbit. Presented at the Vascular Biology meeting, Salt Lake, UT.
19. Pieniaszek, H.J., Garner, D.M., Davidson, A.F., Gillies, P.J., Billheimer, J.T., Jenkins, R.M., Connell, J.M., Hua, T.A., Kieras, C.J., Lam, G.N., Benedek, I.H., and Hainer, J.W. (1996) Plasma 7 hydroxy-4-cholesten-3-one(7-AHC) as an early clinical surrogate marker for LDL-cholesterol reduction following bile acid sequestrant (BAS) administration. Presented at the annual meeting of the American College of Clinical Pharmacology
20. Lawrence, K., Taylor, R., Munzer, D., Grimminger, and Gillies, P. (1996) Macrophage apoE regulation by acetylated LDL and 25-hydroxycholesterol. Presented at the International Vascular Biology meeting in Seattle, WA.
21. Gillies, P., Grimminger, L., Figuly, G., Jensen, J., Royce, S., and Shimshick, E., (1995). DMP 504: A hydrogel bile acid sequestrant, Part 1 - Equilibrium binding and kinetics. Presented at the Drugs Affecting Lipid Metabolism Conference, Houston, TX.

22. Billheimer, J., Fischer, R., Germain, S., Figuly, G., Jensen, J., Royce, S., Gorko, M., Hainer, H., and Gillies, P. (1995). DMP 504: A hydrogel bile acid sequestrant, Part 2 - Mechanism of action studies in the hamster. Presented at the Drugs Affecting Lipid Metabolism Conference, Houston, TX.
23. Hongyaun, Y., Wang, H., Gillies, P., Billheimer, J., Sturley, S., (1995). Restoration of sterol esterification activity to yeast strains lacking acyl-CoA: sterol acyltransferase by expression of a human cDNA. Presented at the Aspen Conference on Bile Acid Metabolism, Aspen, CO.
24. Wang, H., Bunville, J., Dinchuck, J., Benfield, P., and Gillies, P. (1995). Genomic cloning of mouse acyl-CoA: cholesterol acyltransferase and its applications. American Heart Association Meeting, Anaheim, CA
25. Kearney, M. A., Germain, S. J., and Gillies, P. J. (1994). Determination of ACAT activity in freshly isolated monocytes from healthy male subjects: Implications for drug discovery. Presented at the Xth International Symposium on Atherosclerosis meeting, Montreal, Canada.
26. Wang, H. X., Benfield, P. A., Germain, S. G., and Gillies, P. J. (1994). Gene Expression of Acyl-Coenzyme A: Cholesterol Acyltransferase is Upregulated in Human Monocytes during Differentiation and Foam Cell Formation. Presented at the American Heart Association meeting, Dallas, TX.
27. Huff, M. W., Telford, D. E., Barrett, P. H., Billheimer, J. T., and Gillies, P. J. (1993). Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed cholesterol-free diets. Presented at the American Heart Association meeting, Atlanta, GA.
28. Billheimer, J. T., Wexler, R. R., Rudel, L. L. and Gillies, P. J. (1992). The effect of DuP 128 on cholesterol absorption and plasma cholesterol in the African Green Monkey. Presented at the XI International Symposium on Drugs Affecting Lipid Metabolism, Florence, Italy.
29. Billheimer, J. T., Blaney, J., Boswell, G., Delucca, I., Gillies, P. J., Huang, S. M. and Li, H. Y. (1992). Novel 2-aryl-4,4-bis(trifluoromethyl)imidazoles as acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors and antiatherosclerotic agents. Presented at the XII International Symposium on Medicinal Chemistry, Basel, Switzerland.
30. Wilde, R. G., Billheimer, J. T., Gillies, P. J., Higley, C. A., Kezar III, H. S., Maduskuie, T. P., Robinson, C. S., Shimshick, E. J. and Wexler, R. R. (1992). Acyl-CoA: cholesterol acyltransferase . (ACAT) inhibitors: Ureas bearing heterocyclic groups bioisosteric for an imidazole. Presented at the American Chemical Society Meeting, Washington, D.C.
31. Wilde, R. G., Billheimer, J. T., Gillies, P. J., Robinson, C. S., Shimshick, E. J., and Wexler, R. R. (1992). Acyl-CoA: cholesterol acyltransferase

- (ACAT) inhibitors: Imidazole ureas with ether and amine linking elements. Presented at the American Chemical Society Meeting, Washington, D.C.
32. Pennev, P., Maduskuie, T., Billheimer, J. T., Gillies, P. J., Higley, C. A., Johnson, A., Shimshick, E. J., and Wexler, R. R. (1992). Design, synthesis and structure activity relationship studies for a new imidazole series of J774 macrophage specific acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors. Presented at the American Chemical Society Meeting, Washington, D.C.
 33. Maduskuie, T., Billheimer, J. T., Gillies, P. J., Higley, C. A., Pennev, P., Johnson, synthesis and structure activity relationship of a new diphenylamide and phenolic series of acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors. Presented at the American Chemical Society Meeting, Washington, D.C.
 34. Hausner, E., Cockrell, B., Clinton, J. Robinson, C., and Gillies, P. J. (1992). Amelioration of established ocular lipidosis by a calcium antagonist (LaCl₃) in the cholesterol-fed rabbit: Implications for the preclinical evaluation of antiatherosclerotic agents. Presented at the American College of Veterinary Pathologist and Ophthalmologist meeting in San Diego, California.
 35. Gillies, P. J., Robinson, C. S., Higley, C. A., Wexler, R. R. and Billheimer, J. T. (1991). Inhibition of intestinal acyl-CoA:cholesterol acyltransferase (ACAT) by DuP 128 in a cholesterol-fed hamster model of hypercholesterolemia. Presented at the 9th International Symposium on Atherosclerosis, Chicago, Illinois.
 36. Billheimer, J. T., Cromley, D. A., Higley, C. A., Wexler, R. R., Robinson, C. S., and Gillies, P. J. (1991). The diarylthioimidazole, DuP 128, is a potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). Presented at the 9th International Symposium on Atherosclerosis, Chicago, Illinois.
 37. Wexler, R. R., Higley, C. A., Maduskuie, T. P., Pennev, P., Billheimer, J. T., and Gillies, P. J. (1991). Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors: synthesis and SAR studies of a new series of trisubstituted imidazoles. Presented at the 9th International Symposium on Atherosclerosis, Chicago, Illinois.
 38. Mousa, S. A., Pease, L. J., Bozarth, J. M., Hassell, S., Robinson, C. S., Gillies, P. J. and Reilly, T. M. (1990). Increased platelet Gp-IIb/IIIa receptor sensitivity in Watanabe (WHHL) as compared to NZW rabbits. Presented at the 61st Annual Meeting of the American Heart Association, Dallas, Texas.

39. Gillies, P. J., Robinson, C. S., Stadler, J. C., Slone, T., and Carakostos, M. (1989). ACAT inhibitors as regression agents. Presented at the 54th meeting of the European Atherosclerosis Society, Linkoping, Sweden.
40. Gillies, P. J. (1988). Effects of lanthanum chloride on established Coronary Atherosclerosis in the rabbit. Presented at the 21st Hugh Lofland Conference on Arterial Wall Metabolism. Chicago, IL
41. Gillies, P. J., Robinson, C. S., Cockrell, B. Y., and Graepel, G. J. (1988). Effect of lanthanum chloride on established atherosclerosis in the cholesterol-fed rabbit: Biochemical, biophysical, and histological observations. Presented at the 8th International Symposium on Atherosclerosis, Rome, Italy.
42. Gillies, P. J. (1987). Membrane perturbations in atherosclerosis-II. Effects of hypercholesterolemia on the microsomal membrane fluidity of intimal-medial vs medial layers of pig aorta: Implications for the pathogenesis of vasospasm. Presented at the 20th Hugh Lofland Conference on Arterial Wall Metabolism, Winston-Salem, NC
43. Gillies, P. J. (1986). Regulation of arterial ACAT activity: Role of substrate pools and membrane fluidity. Presented at the 19th Hugh Lofland Conference on Arterial Wall Metabolism, Lake George, NY
44. Gillies, P. J., Rathgeb, K. A., and Robinson, C. S. (1985). Membrane cholesterol and the regulation of arterial ACAT activity. Presented at the 7th International Symposium on Atherosclerosis, Melbourne, Australia.
45. Robinson, C. S. and Gillies, P. J. (1985). Decreased arterial microsomal membrane fluidity in atherogenesis. Presented at the 57th Annual Meeting of the American Heart Association, Washington, DC
46. Gillies, P. J. and Lee, K. P. (1984). Inhibition of steroidogenesis in the testes of rats treated with hexafluoroacetone. Presented at the 23rd Annual Society of Toxicology Meeting in Atlanta, GA
47. Gillies, P. J. and Rickard, R. W. (1983). Toxicokinetics of [14C] hexafluoroacetone in the rat. Presented at the 22nd Annual Society of toxicology Meeting in Las Vegas, NA
48. Gillies, P. J. (1983). Studies of the mechanism of hexafluoro-acetone-induced testicular atrophy. Toxicology Research Division, Bureau of Chemical Safety, Health and Research Division, Bureau of Chemical Safety, Health and Welfare Canada, Tunney's Pasture, Ottawa, ON, Canada.
49. Rickard, R. W. and Gillies, P. J. (1983). Hexamethylphosphor- amide (HMPA) nasal carcinogenesis: Covalent binding of [14C] HMPA radioactivity in the nasal turbinates of rats. Presented at the 22nd Annual Society of Toxicology Meeting in Las Vegas, NA

50. Rickard, R. W. and Gillies, P. J. (1982). Hexamethyl-phosphoramide (HMPA) nasal carcinogenesis: Selective retention of ¹⁴C-HMPA radioactivity in target tissues and its inhibition by Metyrapone. Presented at the 21st Annual Society of Toxicology Meeting in Boston, MA
51. Gillies, P. J. and Lee, K. P. (1982). Hexafluoroacetone (HFA) induced testicular atrophy. Presented at the 73rd Annual Meeting of the American Oil Chemists' Society, Toronto, ON, Canada.
52. Rickard, R. W. and Gillies, P. J. (1982). Studies of the mechanism of hexamethylphosphoramide-induced nasal carcinogenesis. Presented as part of the American Society of Pharmacology and Experimental Therapeutics/Society of Toxicology Symposium on Nasal Carcinogenesis, Louisville, KY
53. Gillies, P. J. Norton, R. M., and Bus, J. S. (1981). Altered lipid metabolism in 2,5-hexanedione-induced testicular atrophy and peripheral neuropathy in the rat. Presented at the 20th Annual Society of Toxicology Meeting in San Diego, CA
54. Gillies, P. J. (1981). Evaluation of proposed mechanisms of hexacarbon-induced peripheral neuropathy. Haskell Laboratory for Toxicology and Industrial Medicine, Newark, DE
55. Gillies, P. J. (1981). The biochemical toxicology of hexacarbon-induced peripheral neuropathy. University of Delaware, Newark, DE
56. Gillies, P. J., Norton, R. M., White, E. L., and Bus, J. S. (1980). Studies the inhibition of sterologenesi s in hexacarbon-induced distal axonopathy in sciatic nerves of the rat. Presented at the 19th Annual Society of Toxicology Meeting, Washington, DC.
57. Bus, J. S. and Gillies, P. J. (1980). The role of altered lipid metabolism in hexacarbon-induced neuropathy. Presented as part of the Society of Toxicology Symposium "Unresolved Mechanisms of Toxicity," Washington, DC
58. Gillies, P. J. (1979). Biochemical mechanisms of n-hexane-induced neuropathy. Chemical Industry Institute of Toxicology, Research Triangle Park, NC
59. Gillies, P. J. (1979). Biochemical mechanism of n-hexane-induced peripheral neuropathy. Western Michigan University, MI
60. Gillies, P. J., Norton, R.M., and Bus, J. S. (1979). Effect of 2,5-hexanedione on lipid metabolism in sciatic nerves of the rat. The American Society for Pharmacology and Experimental Therapeutics Meeting in Portland, OR

61. Gillies, P. J. (1978). Effects of di-2-ethylhexyl phthalate on lipid metabolism: A problem with plasticizers? Chemical Industry of Toxicology, Research Triangle Park, NC
62. Gillies, P. J. and Bell, F. P. (1976). In vivo uptake and esterification of labeled carnitine by normal and atherosclerotic rabbit aortas. Presented at the Canadian Federation of Biological Societies Meeting, Halifax, NS, Canada.
63. Gillies, P. J. and Bell, F. P. (1975). Carnitine levels in the normal and atherosclerotic rabbit aortas. Presented at the Canadian Federation of Biological Societies Meeting, Winnipeg, MB, Canada.
64. Gillies, P. J. and Bell, F. P. (1975). The effects of diet on plasma carnitine levels in the rabbit. American Oil Chemists' Society Meeting, Cincinnati, OH

Last updated: January, 2015